In a landmark recognition of scientific ingenuity, the National Institutes of Health (NIH) has announced its latest cohort of recipients for the High-Risk, High-Reward Research Program. Among the distinguished group of 58 investigators selected for their potential to revolutionize the biomedical landscape, three researchers from the Broad Institute of MIT and Harvard have emerged as central figures. Core members Erin Chen and Sam Peng have been honored with the NIH Director’s New Innovator Award, while institute scientist JT Neal has been awarded the prestigious NIH Director’s Transformative Research Award.
These accolades, which target "exceptionally creative scientists proposing highly innovative research," represent a significant vote of confidence in the Broad Institute’s interdisciplinary approach to tackling the most complex challenges in human health. From the microbial landscapes of the human skin to the microscopic signaling pathways of cellular receptors and the massive, automated screening of therapeutics for rare diseases, these researchers are pushing the boundaries of what is possible in modern medicine.
The NIH High-Risk, High-Reward Program: A Catalyst for Paradigm Shifts
The NIH Director’s awards are designed to support unconventional, high-impact research that might otherwise struggle to find funding through traditional mechanisms. By prioritizing the "high-risk" aspect—projects that challenge existing dogmas or propose entirely new methodologies—the NIH aims to accelerate breakthroughs that can fundamentally alter the trajectory of clinical care.
The program is divided into several categories, including the New Innovator Award, which supports early-career investigators of exceptional creativity, and the Transformative Research Award, which funds projects that have the potential to create or overturn fundamental scientific paradigms. By backing these 58 researchers, the NIH is effectively betting on the future of personalized medicine, genomic understanding, and therapeutic innovation.
Profiles in Innovation: The 2024 Broad Institute Honorees
Dr. Erin Chen: Decoding the Skin-Immune Interface
Dr. Erin Chen, who joined the Broad as a core institute member in 2023, occupies a unique space at the intersection of clinical dermatology and fundamental immunology. As an assistant professor of biology at MIT and an attending dermatologist at Massachusetts General Hospital, Dr. Chen’s work is deeply informed by the clinical realities of inflammatory skin disease.
Her New Innovator Award will provide the capital to explore a fascinating biological paradox: how the human body maintains a peaceful coexistence with the trillions of bacteria living on the skin while simultaneously training the immune system to recognize and eliminate pathogens. Specifically, Dr. Chen is investigating the mechanisms by which commensal skin bacteria induce T cell responses that provide protection against disease without triggering the harmful inflammation typically associated with immune activation. If successful, her research could unveil new classes of immunotherapies, offering novel ways to treat chronic inflammatory conditions without suppressing the entire immune system.
Dr. Sam Peng: Visualizing the Language of Cells
Dr. Sam Peng, a core institute member at the Broad and assistant professor of chemistry at MIT, represents the vanguard of biophysical innovation. Since arriving at the Broad in 2022, Dr. Peng has focused on the development of cutting-edge single-molecule microscopy techniques.
The focus of his New Innovator Award is the G-protein-coupled receptor (GPCR) signaling pathway. GPCRs are the largest family of membrane proteins in the human genome and serve as the primary conduits for hormones and neurotransmitters to communicate with the cell. Because GPCRs are involved in nearly every physiological process, their dysregulation is at the root of countless diseases. However, observing these receptors in real-time at the single-molecule level has historically been an immense technical hurdle. Dr. Peng’s work aims to capture the "molecular dance" of these receptors, providing a high-resolution view of how they initiate signaling. This level of insight is expected to be a goldmine for drug developers, potentially opening doors to more precise, effective, and less toxic pharmacological interventions.
Dr. JT Neal: Revolutionizing Rare Disease Discovery
Dr. JT Neal, an institute scientist and director of systems genomics at the Broad, is a veteran of the institute, having spent nearly a decade refining technologies for functional genomics. His receipt of the Transformative Research Award follows his earlier recognition as a New Innovator in 2021, cementing his status as a leader in the field of systems-level drug discovery.
Dr. Neal’s project, titled "Encore," is an ambitious undertaking that seeks to solve one of the most stubborn problems in medicine: the "n-of-1" nature of rare genetic diseases. Many rare diseases lack a single, viable therapeutic candidate. Encore is an experimental and computational platform designed to perform massively parallel drug screening. By leveraging single-cell imaging and transcriptomics, the platform will screen thousands of existing and novel drugs against hundreds of disease-associated phenotypes simultaneously. With the capacity to test over 1.6 million drug-disease combinations, Encore represents a paradigm shift—moving from the traditional "one drug, one disease" model to a high-throughput, systemic approach that could provide hope for patients with rare conditions that have long been considered "un-druggable."
Chronology of Excellence: A Decade of Discovery
The trajectory of these three researchers illustrates the Broad Institute’s commitment to fostering long-term, high-impact scientific inquiry.
- 2014–2020: JT Neal establishes his career at the Broad, focusing on functional genomics and developing the foundational tools for single-cell imaging and transcriptomics that would eventually underpin the Encore platform.
- 2021: JT Neal receives the NIH Director’s New Innovator Award, validating his early work in translating genomic variants into therapeutic hypotheses.
- 2022: Sam Peng joins the Broad as a core institute member, bringing advanced expertise in single-molecule biophysics and chemistry to the institute’s portfolio.
- 2023: Erin Chen joins the Broad, further bridging the gap between clinical dermatology and fundamental immunology.
- 2024: The NIH announces that Chen, Peng, and Neal are among the 58 national recipients of the High-Risk, High-Reward awards, marking a significant milestone for the Broad Institute’s interdisciplinary mission.
Supporting Data: The Magnitude of the Challenge
To understand the scale of these projects, one must look at the data driving the research. For Dr. Neal, the challenge is sheer volume. There are approximately 7,000 known rare diseases, yet only a small fraction have FDA-approved treatments. The Encore platform aims to address this deficit by drastically increasing the "search space" for potential cures.
For Dr. Peng, the challenge is resolution. GPCRs are notoriously dynamic, changing conformation in milliseconds. Existing methods often rely on bulk measurements that average out these critical variations. By achieving single-molecule sensitivity, Dr. Peng’s team is attempting to capture transient states of receptors that are often the "missing link" in understanding how drug molecules actually bind and activate their targets.
Dr. Chen’s work relies on the emerging field of the "skin microbiome." While the gut microbiome has received significant attention, the skin’s microbial ecology remains a frontier. Her research utilizes sophisticated immunological assays to track how specific bacterial antigens educate T cells, providing a quantitative basis for a field that has historically relied on observational data.
Official Responses and Institutional Impact
Broad Institute leadership has lauded the awards as a testament to the culture of collaboration that defines the institute. "The recognition of Erin, Sam, and JT by the NIH is a reflection of their profound commitment to bold, transformative science," said a spokesperson for the Broad. "These awards are not just honors for individual researchers; they are a recognition of the collaborative ecosystems we strive to build—environments where clinicians, chemists, and computational biologists can work in concert to solve the most pressing challenges in human health."
The researchers themselves have echoed this sentiment. Dr. Chen noted that the interdisciplinary environment at the Broad allowed her to bridge the gap between the bedside and the laboratory, a synergy she believes is essential for her T cell research. Dr. Peng highlighted the collaborative spirit at the Broad as being vital for the high-tech instrumentation required for his microscopy work, noting that the access to cutting-edge facilities has been a catalyst for his team’s success.
Implications: The Future of Biomedical Care
The implications of these three projects extend far beyond the laboratory walls.
- Immunotherapy 2.0: If Dr. Chen’s research succeeds, we may move away from broad-spectrum immune suppression—which carries significant side effects—toward "precision" immune modulation. This could redefine the standard of care for psoriasis, eczema, and other inflammatory conditions.
- Next-Generation Pharmacology: By mapping the mechanics of GPCR signaling, Dr. Peng’s work could enable the development of "biased agonists"—drugs that trigger only the beneficial signaling pathways of a receptor while ignoring those that lead to side effects. This is the holy grail of drug design for neurological and endocrine disorders.
- Democratizing Rare Disease Research: The Encore platform promises to lower the barrier for entry in rare disease drug discovery. By systematically mapping the "genotype-to-phenotype-to-therapeutic" landscape, Dr. Neal’s project could create an open-access blueprint that other institutions can use, potentially shortening the timeline for drug discovery from decades to years.
As these three investigators begin their NIH-funded projects, the scientific community will be watching closely. Their work underscores a fundamental truth in modern science: that the most difficult problems—the ones that have resisted solutions for decades—require a combination of daring innovation, high-level technology, and a willingness to embrace risk. Through the support of the NIH High-Risk, High-Reward program, the Broad Institute continues to prove that it is not merely participating in the future of biomedicine; it is actively architecting it.
About the Author
